Third Wave’s InPlex™ CF Molecular Test Receives FDA Clearance

Third Wave Technologies Inc. (NASDAQ: TWTI) today announced that the company has received clearance from the U.S. Food and Drug Administration of its InPlex™ CF Molecular Test. The test simultaneously detects and identifies cystic fibrosis mutations in patient DNA samples. The InPlex™ CF Molecular Test delivers the accuracy of Third Wave’s Invader® chemistry in an easy-to-use microfluidic card developed in collaboration with 3M Co.

Source: Third Wave Technologies